The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance
Authors:
- Philip J. LarsenPLPhilip J. Larsen
- Niels VrangNVNiels Vrang
- Camilla BockCBCamilla Bock
- Troels BockTBTroels Bock
- Lotte Bjerre KnudsenLKLotte Bjerre Knudsen
- 1 August 2008
- journal article
- research article
- Published by Elsevier in Schizophrenia Research
- Vol. 103 (1-3) , 94-103
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: A multicentric, double-blind, placebo-controlled trialSchizophrenia Research, 2007
- Hormonal and Metabolic Effects of Olanzapine and Clozapine Related to Body Weight in RodentsObesity, 2006
- Metabolic Dysregulation With Atypical Antipsychotics Occurs in the Absence of Underlying Disease A Placebo-Controlled Study of Olanzapine and Risperidone in DogsDiabetes, 2005
- Atypical antipsychotic agents and increased risk of diabetes: class action or differential action?Expert Opinion on Drug Safety, 2005
- The pancreatic ductal epithelium serves as a potential pool of progenitor cellsPediatric Diabetes, 2004
- Consensus Development Conference on Antipsychotic Drugs and Obesity and DiabetesDiabetes Care, 2004
- Clozapine and dopamine D3 receptor antisense reduce cocaine‐ and amphetamine‐regulated transcript expression in the rat nucleus accumbens shellSynapse, 2003
- The Atypical Antipsychotics Risperidone, Clozapine and Olanzapine Differ Regarding Their Sedative Potency in RatsNeuropsychobiology, 2003
- The pharmacovigilance of olanzapine: results of a post-marketing surveillance study on 8858 patients in EnglandJournal of Psychopharmacology, 2001
- Pharmacokinetics and tissue distribution of olanzapine in ratsBiopharmaceutics & Drug Disposition, 1999